Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial

Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) inhibitors reduce cardiovascular events in high-risk patients. Whether...

Full description

Bibliographic Details
Main Authors: Andrei C. Sposito, Ikaro Breder, Joaquim Barreto, Jessica Breder, Isabella Bonilha, Marcus Lima, Alessandra Oliveira, Vaneza Wolf, Beatriz Luchiari, Helison R. do Carmo, Daniel Munhoz, Daniela Oliveira, Otavio R. Coelho-Filho, Otavio R. Coelho, Jose Roberto Matos-Souza, Filipe A. Moura, Luiz Sergio F. de Carvalho, Wilson Nadruz, Thiago Quinaglia, Sheila T. Kimura-Medorima, the EXCEED-BHS3 Group
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Cardiovascular Diabetology
Subjects:
Endothelial dysfunction
PCSK9i
Flow-mediated dilation
Online Access:https://doi.org/10.1186/s12933-022-01584-8

Internet

https://doi.org/10.1186/s12933-022-01584-8

Similar Items